Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aslan Pharmaceuticals Ltd ADR (NQ: ASLN )

0.2973 -0.0127 (-4.10%)
Streaming Delayed Price Updated: 1:11 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 85,840
Open 0.3100
Bid (Size) 0.2901 (2)
Ask (Size) 0.2973 (2)
Prev. Close 0.3100
Today's Range 0.2900 - 0.3206
52wk Range 0.2900 - 3.900
Shares Outstanding 402,116,835
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Performance

YTD
-45.95%
-45.95%
1 Month
-33.19%
-33.19%
3 Month
-53.18%
-53.18%
6 Month
-24.35%
-24.35%
1 Year
-92.22%
-92.22%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024
Via InvestorPlace
ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023
Via InvestorPlace
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO
Via Talk Markets
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.